- Home
- MKTW vs BNR Comparison
MKTW vs BNR Comparison
Compare MKTW & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- BNR
- Stock Information
- Founded
- MKTW 1999
- BNR 2014
- Country
- MKTW United States
- BNR China
- Employees
- MKTW N/A
- BNR N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- BNR Medical Specialities
- Sector
- MKTW Technology
- BNR Health Care
- Exchange
- MKTW Nasdaq
- BNR Nasdaq
- Market Cap
- MKTW 46.9M
- BNR 38.3M
- IPO Year
- MKTW N/A
- BNR 2020
- Fundamental
- Price
- MKTW $14.85
- BNR $9.02
- Analyst Decision
- MKTW Hold
- BNR
- Analyst Count
- MKTW 1
- BNR 0
- Target Price
- MKTW $20.00
- BNR N/A
- AVG Volume (30 Days)
- MKTW 14.2K
- BNR 24.9K
- Earning Date
- MKTW 11-06-2025
- BNR 09-08-2025
- Dividend Yield
- MKTW 5.53%
- BNR N/A
- EPS Growth
- MKTW 59.71
- BNR N/A
- EPS
- MKTW 2.83
- BNR N/A
- Revenue
- MKTW $358,121,000.00
- BNR $74,862,782.00
- Revenue This Year
- MKTW N/A
- BNR $136.32
- Revenue Next Year
- MKTW N/A
- BNR N/A
- P/E Ratio
- MKTW $5.11
- BNR N/A
- Revenue Growth
- MKTW N/A
- BNR 5.20
- 52 Week Low
- MKTW $9.08
- BNR $2.18
- 52 Week High
- MKTW $21.74
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- MKTW 26.94
- BNR 55.51
- Support Level
- MKTW $16.13
- BNR $8.91
- Resistance Level
- MKTW $16.57
- BNR $9.77
- Average True Range (ATR)
- MKTW 0.43
- BNR 0.54
- MACD
- MKTW -0.10
- BNR -0.04
- Stochastic Oscillator
- MKTW 0.00
- BNR 62.13
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.